首页 > R&D Systems > R&D Systems/Human NTB-A/SLAMF6 PE-conjugated Antibody/FAB19081P-025/25 Tests

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Human NTB-A/SLAMF6 PE-conjugated Antibody/FAB19081P-025/25 Tests

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

FAB19081P-025-25Tests

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Species ReactivityHumanSpecificityDetects human NTB‑A/SLAMF6 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) BLAME or rhCRACC is observed.SourceMonoclonal Mouse IgG2A Clone # 292811PurificationProtein A or G purified from hybridoma culture supernatantImmunogenMouse myeloma cell line NS0-derived recombinant human NTB‑A/SLAMF6Leu28-Lys225Accession # Q96DU3FormulationSupplied in a saline solution containing BSA and Sodium Azide.LabelPhycoerythrin Flow Cytometry10 µL/106 cellsSee belowShippingThe product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.Stability & StorageProtect from light. Do not freeze.12 months from date of receipt, 2 to 8 °C as supplied. References:Veillette, A. (2006) Immunol. Rev. 214:22. Bottino, C. et al. (2001) J. Exp. Med. 194:235. Fraser, C.C. et al. (2002) Immunogenetics 53:843. Munitz, A. et al. (2005) J. Immunol. 174:110. Valdez, P.A. et al. (2004) J. Biol. Chem. 279:18662. Flaig, R.M. et al. (2004) J. Immunol. 172:6524. Cao, E. et al. (2006) Immunity 25:559. Stark, S. and C. Watzl (2006) Int. Immunol. 18:241. Eissmann, P. and C. Watzl (2006) J. Immunol. 177:3170. Howie, D. et al. (2005) J. Immunol. 174:5931. Kumar, K.R. et al. (2006) Science 312:1665. Long Name:NK-T-B Antigen/SLAM Family Member 6Entrez Gene IDs:114836 (Human)Alternate Names:Activating NK receptor; CD352 antigen; CD352; KALIFLJ50657; Ly108; NK-T-B-antigen; NTBA receptor; NTBA; NTB-A; NTB-AMGC104953; NTBAT- and B-cell antigen; SF2000; SLAM family member 6; SLAMF6Background:NTB-A (NK-T-B-antigen), also known as Ly108 and SLAMF6, is a 60 kDa type I transmembrane glycoprotein that belongs to the SLAM subgroup of the CD2 family (1). Mature human NTB-A contains a 205 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set and one Ig-like C2-set domain. It also contains a 21 aa transmembrane segment and an 84 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs (ITSMs) (2, 3). An alternately spliced isoform is truncated in the cytoplasmic domain and lacks the two ITSMs. Within the ECD, human NTB-A shares 48% aa sequence identity with mouse and rat NTB-A. The ECD of human NTB-A shares 19%‑34% aa sequence identity with comparable regions of human 2B4, BLAME, CD2F-10, CD84, CD229, CRACC, and SLAM. NTB-A is expressed on the surface of NK, T, and B lymphocytes as well as eosinophils (2, 4, 5). It interacts homophilically through weak associations between the Ig-V domains (2, 5‑7). NTB-A functions as an activating coreceptor on NK and T cells (2, 5, 6, 8). Tyrosine phosphorylation in the membrane proximal ITSM enables specific association with EAT-2, an interaction that is required for NTB-A mediated cytotoxicity of NK cells (9). Phosphorylation-dependent NTB-A association with SAP is required for full production of IFN-gammaby NK cells (5, 9). This interaction is independent of EAT-2 binding and appears to involve the membrane distal ITSM (5, 9). NTB-A deficient mice show weakened Th2 responses and elevated levels of neutrophil-derived inflammatory mediators (10). On B cells, NTB-A modulates immunoglobulin class switching and the balance between tolerance and autoimmunity (5, 11).

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。